RARE DISEASE GRANTS AND CONTRIBUTIONS
Advancing Knowledge and Public Health
Pfizer Rare Disease is built on innovation. We pride ourselves in stretching the limits of traditional partnership and collaborative research models by working in new and meaningful ways with innovators in government, academia, advocacy, and across the industry. We believe a networked R&D model that leverages the strengths across all sectors will drive the next generation of breakthrough therapies.
Our ongoing rare disease collaborative research in gene therapy is one example of our cutting-edge approach to developing new therapies. We are continuing to identify and engage new partners to advance our rAAV-based platform and capabilities, leading to several pre-clinical and clinical programs.
Through trusted rare disease partnerships and collaborations—and a shared urgency and relentless passion to make a difference in patients’ lives—Pfizer Rare Disease is supporting programs and initiatives that we believe can benefit the public, advance medical care, and improve patient outcomes.
Rare Disease Grants & Contributions
Here you will find some general information on grants, funding, and other opportunities that are now available to help improve the lives of patients with rare diseases.
Rare Disease Partnerships
We believe that together we gain knowledge faster and increase momentum across the drug development continuum. From discovery, to clinical, to commercial stages, we are looking for partnership opportunities that can to help us with our goal of delivering transformative medicines to patients most in need.
Pfizer Rare Disease partnerships focus on a broad range of therapeutic areas and novel platforms including:
- Endocrine/Inborn Errors of Metabolism
- Gene Therapy
Partnering on Discovery Through Early-Stage Clinical Development
To inquire about partnership opportunities at early stages of development (generally prior to clinical proof-of-concept) in Rare Disease, please contact the Pfizer External Research & Development Innovation (ERDI) group within Worldwide Research & Development (WRD).
Partnering on Late-Stage Clinical Development Through Commercialization
To inquire about partnership opportunities at late-stages of development (generally after clinical proof-of-concept), please contact the Pfizer Worldwide Business Development group within Biopharmaceuticals.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent quality improvement initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.